@article{Du_Zhang_Feng_Chen_Yang_Liu_Xu_Xie_Ma_2016, title={Treatment of nasopharyngeal carcinoma using simultaneous modulated accelerated radiation therapy via helical tomotherapy: a phase II study.}, volume={50}, url={https://www.radioloncol.com/index.php/ro/article/view/2453}, abstractNote={<p><strong><em>Objectives </em></strong><em>To evaluate short-term safety and efficacy of simultaneous modulated accelerated</em><em> </em><em>radiation therapy (SMART) delivered via </em><em>helical tomotherapy</em><em> in patients with nasopharyngeal carcinoma (NPC). </em></p> <p><strong><em>Methods</em></strong><em> Between August 2011 and September 2013, 132 newly diagnosed NPC patients were enrolled for a prospective phase II study. The prescription doses delivered to the gross tumor volume (pGTV<sub>nx</sub>) and positive lymph nodes (pGTV<sub>nd</sub>), the high risk planning target volume (PTV1), and the low risk planning target volume (PTV2), were 67.5Gy (2.25Gy/F), 60Gy (2.0Gy/F), and 54Gy (1.8Gy/F), in 30 fractions, respectively.</em><em> Acute toxicities were evaluated according to the</em><em> established </em><em>RTOG/EORTC</em><em> criteria. This group of patients was compared with the 190 patients in the retrospective P70 study, who were treated between September 2004 and August 2009 with helical tomotherapy, with a dose of </em><em>70</em><em>-</em><em>74Gy/33F/6.5W</em><em> delivered to pGTV</em><em><sub>nx</sub></em><em> and pGTV</em><em><sub>nd</sub></em><em>. </em></p> <p><strong><em>Results</em></strong><em> The median follow-up was 23.7 (12 </em><em>-</em><em> 38) months. Acute radiation related side-effects were mainly problems graded as 1 or 2. Only a small number of patients </em><em>suffere</em><em>d from grade 4 leucopenia (4.5%) </em><em>or thrombocytopenia (2.3%). </em><em>The local relapse-free survival (LRFS), nodal relapse-free survival (NRFS), local-nodal relapse-free survival (LNRFS), distant metastasis-free survival (DMFS) and overall survival (OS) were 96.7%, 95.5%, 92.2%, 92.7% and 93.2%, at 2 years, respectively, with no significant difference compared with the P70 study. </em></p> <p><strong><em>Conclusion</em></strong><em> </em><em>SMART delivered via the helical tomotherapy technique appears to be associated with an acceptable acute toxicity profile and favorable short-term outcomes for patients with NPC. Long-term toxicities and patient outcomes are under investigation.</em><em></em></p>}, number={2}, journal={Radiology and Oncology}, author={Du, Lei and Zhang, Xinxin and Feng, Linchun and Chen, Jing and Yang, Jun and Liu, Haixia and Xu, Shouping and Xie, Chuanbin and Ma, Lin}, year={2016}, month={May} }